TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Comparison of Sugammadex With Neostigmine During Laparoscopic Cholecystectomy or Appendectomy (P05699)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Participants of American Society of Anesthesiologists class 1-3~* Participants of age above or equal to the age of 18 years~* Participants who are scheduled to undergo a laparoscopic cholecystectomy or appendectomy under general anesthesia requiring neuromuscular relaxation with rocuronium, and if applicable, maintenance of neuromuscular blockade~* Participants who have given written informed consent~Exclusion Criteria:~* Participants in whom a difficult intubation because of anatomical malformations is expected~* Participants known or suspected to have neuromuscular disorders affecting NMB~* Participants known or suspected to have a significant renal dysfunction~* Participants known or suspected to have a severe hepatic dysfunction~* Participants known or suspected to have (family) history of malignant hyperthermia~* Participants known or suspected to have an allergy to opioids, muscle relaxants or other medication used during general anesthesia~* Participants in whom the use of neostigmine and/or atropine is contraindicated~* Female participants who are pregnant (pregnancy will be excluded for women both from medical history and by a human chorionic gonadotropin (hCG) test within 24h before surgery, except for women who are not of childbearing potential, i.e. at least 2 years menopausal or have undergone tubal ligation or a hysterectomy)~* Female participants who are breast-feeding~* Participants who participated in another clinical trial not pre-approved by the sponsor, within 30 days of entering into trial 19.4.318 (P05699)~* Participants who have already participated in a sugammadex trial

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Sugammadex (Type: EXPERIMENTAL): 4.0 mg.kg-1 sugammadex at 1-2 PTC
- Neostigmine (Type: EXPERIMENTAL): 50 µg.kg-1 neostigmine (with atropine in a ratio of 5:1 for neostigmine:atropine) at reappearance of T2

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Pharmacological Treatment of Rett Syndrome With Glatiramer Acetate (Copaxone)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Female patients with genetically confirmed Rett Syndrome (RTT)~* Age: 10 or more years old. Selection of the age is based on the available evidence of the safety of Glatiramer Acetate (GA) in this group, and the relative homogeneity/stability of the phenotype, which is not expected to spontaneously change within a 6 month period at this age~* Ambulatory (with our without support)~Exclusion Criteria:~* Prolonged Qtc (obtained within 30 days prior to enrollment)~* Presence of co morbid non-Rett related disease~* Presence of immunodeficiency requiring intravenous immunoglobulin 3 (IVIG 3) months prior to enrollment~* Allergy/sensitivity to GA or mannitol~* Inability or unwillingness of legal guardians to give written informed consent

- Gender: FEMALE
- Minimum Age: 10 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Copaxone (Type: EXPERIMENTAL): Dose escalation:~Study drug will be administered once a week for 4 weeks, twice a week for 4 weeks and daily for 24 weeks. Drug is administered as a subcutaneous injection.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Ultrasound Guided Aspiration of Hydrosalpingeal Fluid and IVF-ET Outcomes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with unilateral or bilateral hydrosalpinges visible by ultrasound~* Age between 18 - 37 years~* Period of infertility \> 1 year~* Body mass index between 19-29~* Normal basal luteinizing hormone (LH), follicle stimulating hormone (FSH) and prolactin concentrations~* Normal recent semen analysis (according to World Health Organization criteria)~Exclusion Criteria:~* Uterine fibroid requiring surgical removal~* Endometriosis~* Male factor of infertility requiring ICSI~* Previous IVF cycles~* History of recurrent miscarriage~* Endocrinologic disorders~* Presence of systemic disease contraindicating pregnancy

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 37 Years
- Healthy Volunteers: f

Study Arms:
- 1: Hydrosalpinx needle aspiration (Type: EXPERIMENTAL): After the retrieval of oocytes an aspiration needle is inserted into the hydrosalpinx under ultrasonographic guidance and suction is applied to aspirate the hydrosalpingeal fluid completely .
- 2. no aspiration (Type: NO_INTERVENTION): IVF-ET is done without prior aspiration of hydrosalpingeal fluid

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: 3-year Follow-up Study in Patients Previously Treated With TMC435-Containing Regimen for the Treatment of Hepatitis C Virus Infection

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Have previously participated in a Phase IIb or Phase III study~* Must have received at least one dose of TMC435 in that study~* Has completed the last post-therapy follow-up visit of the previous (LPVPS) study~Exclusion Criteria:~* Must be currently enrolled or plan to enroll in another study with an investigational drug or invasive investigational medical device~* Have received antiviral or immunomodulating treatment, including therapeutic vaccines, for hepatitis C virus (HCV) between LPVPS and the screening visit of present study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Group 1: TMC 435 - Patients With SVR at LPVPS (Type: OTHER): Patients with sustained virologic response (SVR) who completed last post-therapy follow-up visit of the previous study (LPVPS) \[Phase IIb or Phase III\] in which they received a TMC435-containing regimen for the treatment of HCV infection.
- Group 2: TMC 435 - Patients With No SVR at LPVPS (Type: OTHER): Patients with no sustained virologic response (SVR) who completed last post-therapy follow-up visit of the previous study (LPVPS) \[Phase IIb or Phase III\] in which they received a TMC435-containing regimen for the treatment of HCV infection.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Immunogenicity of a Zoster Vaccine in SLE

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. SLE patients who fulfill ≥4 of the 1997 ACR (17) or the 2012 SLICC/ACR criteria for SLE (18)~2. Age ≥18 years~3. Clinically inactive disease with SELENA-SLEDAI score \<6 (see below) and receiving stable dose of immunosuppressive agents for ≥6 months~4. History of varicella (chickenpox) or herpes zoster infection in the past~5. Willing to comply with all study procedures~Exclusion Criteria:~1. Active infection, including upper respiratory tract infection~2. Active untreated tuberculosis~3. Human immunodeficiency virus (HIV) infection~4. Lymphocyte count \<500/mm2~5. Reduced serum IgG, IgA or IgM level (below normal range)~6. Serum creatinine \>200umol/L~7. History of hematological malignancies (eg. lymphoma, leukaemia) and other solid tumors~8. Patients receiving doses of immunosuppressive agents exceeding the following:~   * Prednisolone (\>15mg) or equivalent~  * Azathioprine (\>100mg/day)~  * Mycophenolate mofetil (\>1000mg/day)~  * Cyclosporin A (\>100mg/day)~  * Tacrolimus (\>3mg/day)~  * Methotrextate (\>15mg/week)~  * Cyclophosphamide (any dose)~  * Biological agents eg. rituximab, belimumab (any dose)~9. Patients who are pregnant or plan to become pregnancy within one year of study entry~10. Patients who cannot give a written consent (mentally incapable or illiterate)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- SLE (vaccine) (Type: ACTIVE_COMPARATOR): Zostavax SC injection (0.65ml)
- SLE (placebo) (Type: PLACEBO_COMPARATOR): Placebo SC injection (normal saline 0.65ml)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: TA-8995: Its Use in Patients With Mild Dyslipidaemia (TULIP)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 9.0

Eligibility Criteria:
Inclusion Criteria:~* Fasting LDL-C levels \>2.5 mmol/L and \<4.5 mmol/L, HDL-C levels \<1.8 mmol/L and \>0.8 mmol/L, and TG levels \<4.5 mmol/L after run in or washout of existing therapies~* Not on lipid-altering therapy at screening or on lipid-altering treatment regimens at screening~Exclusion Criteria:~* Body mass index \>32 kg/m2;~* Participation in another clinical study involving an investigational or marketed drug within 30 days prior to enrolment (Visit 2);~* Any clinical manifestation of atherosclerotic vascular disease;~* Diagnosis of type 1 diabetes;~* Uncontrolled type 2 diabetes: haemoglobin A1c \>8%;~* Uncontrolled hypertension: sitting systolic blood pressure \>160 mmHg and/or sitting diastolic blood pressure \>90 mmHg;~* History of hyperaldosteronism;~* Active muscle disease or persistent creatine kinase concentration \>3 × the upper limit of normal (ULN). One retest will be allowed after 1 week to verify the result;

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Group 1 (Type: PLACEBO_COMPARATOR): TA-8995 0mg (placebo) \& placebo statin
- Group 2 (Type: EXPERIMENTAL): TA-8995 1mg \& placebo statin
- Group 3 (Type: EXPERIMENTAL): TA-8995 2.5mg \& placebo statin
- Group 4 (Type: EXPERIMENTAL): TA-8995 5mg \& placebo statin
- Group 5 (Type: EXPERIMENTAL): TA-8995 10mg \& placebo statin
- Group 6 (Type: ACTIVE_COMPARATOR): TA-8995 0mg (placebo) \& atorvastatin 20mg
- Group 7 (Type: ACTIVE_COMPARATOR): TA-8995 10mg \& atorvastatin 20mg
- Group 8 (Type: ACTIVE_COMPARATOR): TA-8995 0mg (placebo) \& rosuvastatin 10mg
- Group 9 (Type: ACTIVE_COMPARATOR): TA-8995 10mg \& rosuvastatin 10mg

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Lipiodol as an Imaging Biomarker in Patients With Primary and Metastatic Liver Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. 18 years of age or older.~2. Eastern Cooperative Oncology Group (ECOG) Performance Status of 0-2.~3. Childs class of A or B (up to 9).~4. Hepatocellular carcinoma (HCC) is unresectable with liver-predominant disease or subject has HCC and refused surgery or subject is diagnosed hepatic metastases from any solid tumor. (Multifocal HCC is acceptable, no diffuse HCC).~5. Subject is voluntarily participating in the study and has signed the informed consent.~Exclusion Criteria:~1. Contraindications to doxorubicin, cisplatin, or mytomycin-c administration (or specific mixture of chemotherapy drugs to be used).~2. Evidence of severe or uncontrolled systemic diseases.~3. Congestive cardiac failure \>NYHA class 2 MI within 6 months, active coronary artery disease, cardiac arrhythmias requiring anti-arrhythmic therapy other than beta blockers or digoxin, unstable angina, or laboratory finding that in the view of the investigator makes it undesirable for the patient to participate in the trial.~4. Known allergy to Lipiodol (Ethiodol), poppy seed oil, or iodinated contrast agents (that cannot be adequately mitigated with pre-procedure medication).~5. Main portal vein thrombosis is excluded; segmental or branch portal vein thrombosis is acceptable.~6. Subject is breastfeeding.~7. Subject is pregnant

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Lipiodol (Type: OTHER): Lipiodol, 10cc per TACE.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Treating Insulin Resistance as a Strategy to Improve Outcome in Refractory Bipolar Disorder

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. 18 years of age or older~2. diagnosis of BD I or II~3. non-remitting BD as defined by the presence of mood symptoms of at least moderate severity, indicated by a MADRS score ≥ 15 despite being on optimal treatment according to the CANMAT/APA guidelines~4. HOMA-IR ≥ 1.8, indicating IR (subjects will have FPG and FSI testing done to determine whether they have IR or T2D)~5. current episode of depression 4 weeks or longer in duration~6. on a stable optimal dose of mood stabilizing treatment for at least 4 weeks prior to study entry~Exclusion Criteria:~1. Diagnoses of organic mood disorder, mood disorder not otherwise specified, alcohol dependence, T1D or T2D~2. presence of rapid cycling (by DSM-5 criteria), mania, (indicated by a Young Mania Rating Scale \[YMRS\] score \> 15), or suicide ideation (current score of 5 on the Suicidal Ideation section of the Columbia-Suicide Severity Rating scale \[C-SSRS\])~3. patient receiving metformin \< 2 weeks prior to study entry~4. metformin allergy or sensitivity~5. metformin contraindicated where liver function tests \> three times the upper limit of normal, estimated glomerular filtration rate (eGFR) \< 30, CBC revealing megaloblastic anemia or pre-existing untreated B12 deficiency~6. pregnancy or breastfeeding~7. lactose intolerance, diagnosed by a physician~8. chronic use of narcotic medications~9. patient lacks full capacity to consent to study participation.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): Placebo comparator to be given twice daily, once with breakfast and once with supper
- Metformin (Type: EXPERIMENTAL): Metformin 2000 mg daily to be given as follows: 1000 mg with breakfast and 1000 mg with supper

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A 19-week Cognition Study of Levetiracetam in Children With Partial Onset Seizures

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Pediatric subjects (4 - 16 years old) diagnosed with refractory partial onset seizures for a minimum of six months prior to Visit 1 experiencing at least two partial onset seizures during the four weeks prior to Visit 1 will be enrolled~* Subjects should be on a stable regimen of one or a maximum of two other antiepileptic drugs (AEDs) for at least 2 weeks prior to Visit 1~* Subject must have an Intelligence Quotient (IQ) as assessed during Visit 1 of at least 70~* Subject and parent/guardian should be fluent in English~Exclusion Criteria:~* Subject must not have had previous treatment with levetiracetam unless, in the opinion of the investigator, the subject's previous treatment was inadequate in dose or duration to provide an accurate assessment of the therapy, or the effect of levetiracetam was confounded by concomitant medication~* Subject is receiving benzodiazepines on a routine or chronic basic and is unable to discontinue use four weeks prior to Visit 1~* Subject has seizures too close together to accurately count~* Subject has a current psychiatric disorder other than mild to moderate attention deficit, behavior, or learning disorders

- Gender: ALL
- Minimum Age: 4 Years
- Maximum Age: 16 Years
- Healthy Volunteers: f

Study Arms:
- Levetiracetam (LEV) (Type: EXPERIMENTAL): Oral tablets or oral solution at 20-60 mg/kg/d, divided into twice daily dosing.
- Matching Placebo (PBO) (Type: PLACEBO_COMPARATOR): Oral tablets and oral solution.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy of Combination Saxagliptin & Dapagliflozin Added to Metformin to Treat Subjects With Type 2 Diabetes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects with Type 2 diabetes mellitus (T2DM) with HbA1c ≥ 8.0% and ≤ 12.0%~* Stable metformin therapy dose of ≥ 1500mg for at least 8 weeks prior to screening~* Body mass index (BMI) ≤ 45.0kg/m2~Exclusion Criteria:~* Estimated glomerular filtration rate (eGFR) \< 60mL/min/1,73m2 and Serum Creatinine (Scr) ≥ 1.5 mg/dL in males or ≥ 1.4 mg/dL in females~* Uncontrolled hypertension Systolic Blood Pressure (SBP) ≥ 160mmHg and/or Diastolic Blood Pressure (DBP) ≥ 100mmHg~* Hepatic disease~* Cardiovascular disease within 3 months

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Arm 1: Saxagliptin+Metformin XR+Placebo (Type: ACTIVE_COMPARATOR): None
- Arm 2: Dapagliflozin+Metformin XR+Placebo (Type: ACTIVE_COMPARATOR): None
- Arm 3: Saxagliptin+Dapagliflozin+Metformin XR (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Heart Rate Response to Atropine Doses Less Than 0.1mg IV to Anesthetized Infants

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Age : 0-2 years old~2. Weight : less than the 95th percentile for age and height ( no more than 15kg )~3. ASA classification : I-II~4. Meets the hospital and department of anesthesiology guidelines with respect to peri-operative care~Exclusion Criteria:~1. History of heart disease~2. Any condition predisposing to arrhythmia~3. Any medication known to influence the heart rate~4. Child taking anti-cholinergic medication routinely~5. The use of succinylcholine anticipated (will cause bradycardia)~6. Rapid sequence intubation is required (due to aspiration risk)~7. Known difficult airway (may be difficult to bag mask ventilate)

- Gender: ALL
- Minimum Age: 1 Day
- Maximum Age: 2 Years
- Healthy Volunteers: f

Study Arms:
- Infants and children less than 15Kg. (Type: EXPERIMENTAL): This group consists of children who are ASA physical status I and II, less than 2 years of age and scheduled for elective surgical procedure and weigh less than 15Kg will receive atropine 5 mcg/kg IV during sevoflurane anesthesia.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Cognitive Behavioral Therapy +/- Armodafinil for Insomnia and Fatigue Following Chemotherapy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~1. Have a diagnosis of cancer.~2. Be able to understand written and spoken English~3. Be able to swallow medication~4. Have preferred sleep phase between 7:30 pm and 11:00 am~5. Be willing to discontinue any medications/OTCs/Herbals for sleep for the 11-week study period~6. Be presumed to be in a state of cancer remission; use of tamoxifen, an aromatase inhibitor, and/or Herceptin is permitted~7. Self-report problems with insomnia for at least three months and that the insomnia began or got worse with the onset of cancer or treatment~8. Have completed chemotherapy and or radiation not less than one month ago. Note: Both types of treatment must be completed at least one month ago if patient receives chemotherapy and radiation therapy and there is no outer limit to how long ago treatments were completed.)~9. Report insomnia on the SDS-CL at a frequency of at least 3 days a week~Exclusion Criteria:~1. Have ever taken modafinil or had CBT-I therapy. CBT-I therapy for the sake of this protocol will be defined as any cognitive behavioral-based treatment for insomnia that includes a sleep restriction component.~2. Have an unstable medical or psychiatric illness (Axis I-current or within the last 5 years)~3. Have a history of seizures or severe headaches, or uncontrolled cardiac disease or hypertension~4. Be presently taking an anticoagulant or a corticosteroid~5. Have taken amphetamines (e.g., methylphenidate, pemoline \[Cylert®\] or similar psycho stimulants) within the past 30 days~6. Be currently pregnant or nursing~7. Have a history of substance abuse, or meet criteria for current alcohol abuse or dependence as assessed by a CAGE test score \>=2 or an Alcohol Use Disorders Identification Test (AUDIT) score \>=13~8. Have surgery planned within the study period~9. Have have ever been diagnosed with sleep apnea or have sleep apnea as indicated by endorsing either question 11 (I wake up choking or gasping for air) or question 12 (My bed partner has noticed that I seem to stop breathing) on the Sleep Disorders Symptom Check at the Often or Frequently level.

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- 1 - CBT-I + placebo (Type: EXPERIMENTAL): CBT-I and placebo
- 2 - CBT-I + Armodafinil (Type: EXPERIMENTAL): CBT-I + Armodafinil
- 3 - Placebo only (Type: PLACEBO_COMPARATOR): Placebo only
- 4 - Armodafinil only (Type: EXPERIMENTAL): Armodafinil only

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete